NeuraLight Seed

Employees 5+
Primary contact

NeuraLight is building an AI-driven platform to accelerate and improve drug development, monitoring, and care for patients with neurological disorders using information captured with a standard smartphone or webcam. The company's vision is a world where neurological disorders can be prevented, diagnosed, and treated effectively, and people live longer, healthier lives.
Employees 5+
Primary contact

Funding 💰

Total $5.5M
Last round 🔗 October 28, 2021.
Select investors MS&AD Ventures, Matias Ventures, Tuesday Capital, Operator Partners, Kli Capital, VSC Ventures

Key people 🧑‍🤝‍🧑

Highlights

  • Huge market: Over 1 billion people worldwide suffer from neurological disorders, making them the leading cause of global disability.
  • Beyond patients: The company's platform can also help accelerate clinical trials and increase the probability of success of future therapies for Parkinson's, Alzheimer's, Multiple Sclerosis and other neurodegenerative diseases.
  • Proprietary tech: NeuraLight's patent-pending Computer Vision and Deep Learning algorithms can attain sub‑pixel resolution using just a standard smartphone or webcam.
  • Experienced CEO: Micha Breakstone was previously the co-founder and former president of Chorus.ai, which sold to ZoomInfo for $575 million in 2021. 🔗
  • Eyes on the U.S. market: NeuraLight actually has two headquarters - one in Austin, Texas and the other one in Tel Aviv.
Last update: February 15, 2022